Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AURA Aura Biosciences	$6.55 +1.2%	$6.61	$4.34 ▼ $12.38	$406.89M	0.46	162,914 shs	200,421 shs
IVA Inventiva	$4.47 +4.9%	$3.44	$1.53 ▼ $4.70	$427.60M	0.73	31,426 shs	13,206 shs
KMDA Kamada	$7.18 +1.8%	$7.48	$5.17 ▼ $9.15	$412.92M	0.93	50,824 shs	21,642 shs
SPRO Spero Therapeutics	$1.87 +0.5%	$2.49	$0.51 ▼ $3.22	$105.24M	1.39	798,210 shs	301,332 shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AURA Aura Biosciences	0.00%	-2.53%	-9.41%	+11.21%	-13.70%
IVA Inventiva	0.00%	+2.52%	+42.63%	+43.04%	+86.25%
KMDA Kamada	0.00%	-2.31%	-6.99%	+8.30%	+25.52%
SPRO Spero Therapeutics	0.00%	-2.09%	-19.74%	+168.56%	+36.50%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AURA Aura Biosciences	1.8337 of 5 stars	3.6	0.0	0.0	2.6	2.5	0.0
IVA Inventiva	3.4259 of 5 stars	3.4	5.0	0.0	3.3	1.7	0.6
KMDA Kamada	4.6812 of 5 stars	3.3	5.0	0.0	3.4	1.7	4.4
SPRO Spero Therapeutics	3.9577 of 5 stars	3.3	3.0	4.7	2.7	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AURA Aura Biosciences	3.11	Buy	$22.00	235.88% Upside
IVA Inventiva	2.80	Moderate Buy	$10.40	132.66% Upside
KMDA Kamada	2.67	Moderate Buy	$13.00	81.06% Upside
SPRO Spero Therapeutics	2.50	Moderate Buy	$5.00	167.38% Upside

Current Analyst Ratings Breakdown

Latest SPRO, KMDA, AURA, and IVA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/19/2025	AURA Aura Biosciences	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/13/2025	AURA Aura Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$22.00
5/28/2025	AURA Aura Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$22.00

(Data available from 8/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AURA Aura Biosciences	N/A	N/A	N/A	N/A	$3.04 per share	N/A
IVA Inventiva	$9.95M	42.97	N/A	N/A	($1.21) per share	-3.69
KMDA Kamada	$160.95M	2.57	$0.49 per share	14.60	$4.51 per share	1.59
SPRO Spero Therapeutics	$47.98M	2.19	N/A	N/A	$0.85 per share	2.20

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AURA Aura Biosciences	-$86.92M	-$1.96	N/A	N/A	N/A	N/A	-64.44%	-54.24%	11/11/2025 (Estimated)
IVA Inventiva	-$199.34M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	9/25/2025 (Estimated)
KMDA Kamada	$14.46M	$0.34	21.12	22.44	0.76	11.22%	7.41%	5.18%	11/12/2025 (Estimated)
SPRO Spero Therapeutics	-$68.57M	-$0.98	N/A	N/A	N/A	-110.35%	-120.27%	-55.61%	11/13/2025 (Estimated)

Latest SPRO, KMDA, AURA, and IVA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	AURA Aura Biosciences	-$0.49	-$0.47	+$0.02	-$0.47	N/A	N/A
8/13/2025	Q2 2025	KMDA Kamada	$0.09	$0.13	+$0.04	$0.13	$158.59 million	$44.75 million
8/12/2025	Q2 2025	SPRO Spero Therapeutics	-$0.38	-$0.03	+$0.35	-$0.03	$11.00 million	$14.19 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AURA Aura Biosciences	N/A	N/A	N/A	N/A	N/A
IVA Inventiva	N/A	N/A	N/A	N/A	N/A
KMDA Kamada	N/A	N/A	N/A	N/A	N/A
SPRO Spero Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AURA Aura Biosciences	N/A	12.39	12.39
IVA Inventiva	N/A	0.92	0.92
KMDA Kamada	N/A	4.00	2.21
SPRO Spero Therapeutics	N/A	3.97	3.97

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AURA Aura Biosciences	96.75%
IVA Inventiva	19.06%
KMDA Kamada	20.38%
SPRO Spero Therapeutics	25.60%

Insider Ownership

Company	Insider Ownership
AURA Aura Biosciences	6.30%
IVA Inventiva	32.00%
KMDA Kamada	36.10%
SPRO Spero Therapeutics	5.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AURA Aura Biosciences	50	62.12 million	58.21 million	Not Optionable
IVA Inventiva	100	95.66 million	65.05 million	Not Optionable
KMDA Kamada	360	57.51 million	36.75 million	Optionable
SPRO Spero Therapeutics	150	56.28 million	53.18 million	Optionable

SPRO, KMDA, AURA, and IVA Headlines

Recent News About These Companies

Down 17.7% in 4 Weeks, Here's Why Spero Therapeutics (SPRO) Looks Ripe for a Turnaround

August 19, 2025 | zacks.com

Spero Therapeutics (NASDAQ:SPRO) Releases Earnings Results, Beats Expectations By $0.32 EPS

August 14, 2025 | marketbeat.com

Spero Therapeutics, Inc. (NASDAQ:SPRO) Q2 2025 Earnings Call Transcript

August 13, 2025 | insidermonkey.com

Spero Therapeutics, Inc.: Spero Therapeutics Announces Second Quarter 2025 Operating Results and Provides a Business Update

August 13, 2025 | finanznachrichten.de

Spero Therapeutics Reports Q2 2025 Results and Trial Success

August 13, 2025 | msn.com

Spero Therapeutics Reports Q2 2025 Financial Results

August 12, 2025 | msn.com

Spero Therapeutics, Inc. (SPRO) Q2 2025 Earnings Call Transcript

August 12, 2025 | seekingalpha.com

Spero Therapeutics Announces Second Quarter 2025 Operating Results and Provides a Business Update

August 12, 2025 | globenewswire.com

Spero Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update on Tuesday, August 12, 2025

August 5, 2025 | globenewswire.com

Spero Therapeutics (SPRO) Expected to Announce Quarterly Earnings on Monday

July 28, 2025 | marketbeat.com

While institutions own 20% of Spero Therapeutics, Inc. (NASDAQ:SPRO), retail investors are its largest shareholders with 54% ownership

June 28, 2025 | finance.yahoo.com

Spero Therapeutics, Inc. (SPRO) Cash Flow - Yahoo Finance

June 26, 2025 | finance.yahoo.com

Spero Therapeutics -- Additional Upside Potential Following Positive Phase 3 Results

June 11, 2025 | seekingalpha.com

Why Spero Therapeutics, Inc. (SPRO) Surged Last Week

May 31, 2025 | msn.com

Why Spero Therapeutics, Inc. (SPRO) Surged Last Week

May 31, 2025 | insidermonkey.com

GSK & Spero Therapeutics announce PIVOT-PO phase III study for tebipenem HBr stopped early for efficacy following review by IDMC

May 30, 2025 | pharmabiz.comP

Spero Therapeutics rockets on positive Phase III study for tebipenem HBr

May 29, 2025 | thepharmaletter.comT

Spero Therapeutics Jumps as Oral Carbapenem Hits Phase 3 Milestone

May 29, 2025 | msn.com

SPRO Stock Soars 245% on GSK-Partnered UTI Drug Meeting Study Goal

May 29, 2025 | zacks.com

GSK, Spero report Phase 3 win for UTI antibiotic; Spero's stock soars

May 28, 2025 | endpts.comE

GSK's $66M bet on Spero's rejected UTI antibiotic pays off with a phase 3 win

May 28, 2025 | fiercebiotech.comF

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

SPRO, KMDA, AURA, and IVA Company Descriptions

Aura Biosciences NASDAQ:AURA

$6.55 +0.08 (+1.24%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$6.90 +0.35 (+5.34%)

As of 05:20 AM Eastern

Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.

Inventiva NASDAQ:IVA

$4.47 +0.21 (+4.93%)

Closing price 08/22/2025 03:57 PM Eastern

Extended Trading

$4.47 +0.00 (+0.11%)

As of 04:05 AM Eastern

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company was founded in 2011 and is headquartered in Daix, France.

Kamada NASDAQ:KMDA

$7.18 +0.13 (+1.84%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$7.16 -0.02 (-0.28%)

As of 04:42 AM Eastern

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.

Spero Therapeutics NASDAQ:SPRO

$1.87 +0.01 (+0.54%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$1.86 -0.01 (-0.27%)

As of 04:43 AM Eastern

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time